source
- AstraZeneca’s newly approved pill fails frontline breast cancer studyEtcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
- Cellectis abandons CAR-T programs, shifts focus to in vivo gene editingCellectis announced it will discontinue its donor-derived CAR‑T programs and redirect its efforts toward in vivo gene‑editing medicines. The company said the commercial and clinical landscape for…